120 related articles for article (PubMed ID: 16870107)
21. [Etanercept].
Mühlhäuser U; Münzel F; Eschenhagen T
Dtsch Med Wochenschr; 2003 Aug; 128(34-35):1775-8. PubMed ID: 12934172
[No Abstract] [Full Text] [Related]
22. The effectiveness of a biologic agent on axial manifestations of psoriatic arthritis. A twelve months observational study in a group of patients treated with etanercept.
Lubrano E; Spadaro A; Marchesoni A; Olivieri I; Scarpa R; D'Angelo S; Salvarani C; Mathieu A; Cauli A; Ferrara N; Helliwell P
Clin Exp Rheumatol; 2011; 29(1):80-4. PubMed ID: 21345296
[TBL] [Abstract][Full Text] [Related]
23. Local perfusion of the tumor necrosis factor alpha blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss.
Van Wijk F; Staecker H; Keithley E; Lefebvre PP
Audiol Neurootol; 2006; 11(6):357-65. PubMed ID: 16988499
[TBL] [Abstract][Full Text] [Related]
24. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis.
Anandarajah AP; Schwarz EM; Totterman S; Monu J; Feng CY; Shao T; Haas-Smith SA; Ritchlin CT
Ann Rheum Dis; 2008 Mar; 67(3):296-301. PubMed ID: 17967829
[TBL] [Abstract][Full Text] [Related]
25. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
[TBL] [Abstract][Full Text] [Related]
26. TNFalpha therapy in psoriatic arthritis and psoriasis.
Mease P
Ann Rheum Dis; 2004 Jul; 63(7):755-8. PubMed ID: 15194567
[No Abstract] [Full Text] [Related]
27. Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept.
Esposito M; Giunta A; Babino G; Schipani C; Marchei M; Chimenti MS
Eur J Dermatol; 2012; 22(1):151-2. PubMed ID: 22155373
[No Abstract] [Full Text] [Related]
28. Psoriatic onychopachydermoperiostitis: improvement with etanercept.
Dans M; Hivnor C; van Voorhees AS
Br J Dermatol; 2005 Oct; 153(4):858-9. PubMed ID: 16181482
[No Abstract] [Full Text] [Related]
29. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
[TBL] [Abstract][Full Text] [Related]
30. Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept.
Fiocco U; Ferro F; Vezzù M; Cozzi L; Checchetto C; Sfriso P; Botsios C; Ciprian L; Armellin G; Nardacchione R; Piccoli A; Todesco S; Rubaltelli L
Ann Rheum Dis; 2005 Jun; 64(6):899-905. PubMed ID: 15567814
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPArE trial.
Gladman DD; Bombardier C; Thorne C; Haraoui B; Khraishi M; Rahman P; Bensen W; Syrotuik J; Poulin-Costello M
J Rheumatol; 2011 Jul; 38(7):1355-62. PubMed ID: 21572156
[TBL] [Abstract][Full Text] [Related]
32. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection.
Linardaki G; Katsarou O; Ioannidou P; Karafoulidou A; Boki K
J Rheumatol; 2007 Jun; 34(6):1353-5. PubMed ID: 17552060
[TBL] [Abstract][Full Text] [Related]
33. Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept.
van Luijn JC; Danz M; Bijlsma JW; Gribnau FW; Leufkens HG
Scand J Rheumatol; 2011 May; 40(3):183-91. PubMed ID: 20858147
[TBL] [Abstract][Full Text] [Related]
34. Etanercept therapy of psoriatic arthritis in a patient with liver cirrhosis.
Lehnen M; Franckson T; Korber A; Grabbe S; Dissemond J
Acta Derm Venereol; 2005; 85(4):351-2. PubMed ID: 16191861
[No Abstract] [Full Text] [Related]
35. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study.
de Vlam K; Lories RJ
Rheumatology (Oxford); 2006 Mar; 45(3):321-4. PubMed ID: 16234275
[TBL] [Abstract][Full Text] [Related]
36. Guideline for anti-TNF-alpha therapy in psoriatic arthritis.
Kyle S; Chandler D; Griffiths CE; Helliwell P; Lewis J; McInnes I; Oliver S; Symmons D; McHugh N;
Rheumatology (Oxford); 2005 Mar; 44(3):390-7. PubMed ID: 15695305
[No Abstract] [Full Text] [Related]
37. In etanercept-treated psoriatic arthritis patients clinical improvement correlated with an increase of serum cortisol relative to other adrenal hormones.
Atzeni F; Sarzi-Puttini P; DePortu S; Cutolo M; Carrabba M; Straub RH
Clin Exp Rheumatol; 2008; 26(1):103-8. PubMed ID: 18328154
[TBL] [Abstract][Full Text] [Related]
38. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
Pomerantz RG; Mody E; Husni ME; Qureshi AA
J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
[TBL] [Abstract][Full Text] [Related]
39. Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study.
Cohen S; Shoup A; Weisman MH; Harris J
Otol Neurotol; 2005 Sep; 26(5):903-7. PubMed ID: 16151336
[TBL] [Abstract][Full Text] [Related]
40. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein.
Zhou H
J Clin Pharmacol; 2005 May; 45(5):490-7. PubMed ID: 15831771
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
